Premium
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts
Author(s) -
Strati Paolo,
GarciaManero Guillermo,
Zhao Chong,
Kadia Tapan,
Borthakur Gautam,
Konopleva Marina,
Daver Naval,
DiNardo Courtney D.,
Short Nicholas J.,
Yilmaz Musa,
Naqvi Kiran,
Alvarado Yesid,
Pierce Sherry A.,
Cortes Jorge,
BuesoRamos Carlos,
Kantarjian Hagop,
Ravandi Farhad
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25490
Subject(s) - medicine , myelodysplastic syndromes , chemotherapy , bone marrow , hypomethylating agent , oncology , azacitidine , biology , genetics , gene expression , dna methylation , gene